A head-to-head comparison of the antimicrobial activities of 30 ultra-short antimicrobial peptides against Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans

International Journal of Peptide Research and Therapeutics

Volumn 21, Issue 1, 2015, Pages 21-28

  Lau, Qiu Ying ^a   Choo, Xing Yao ^a   Lim, Zhi Xue ^a   Kong, Xin Ni ^a   Ng, Fui Mee ^a   Ang, Melgious J Y ^a   Hill, Jeffrey ^a   Chia, C S Brian ^a  

^a Agency for Science   (Singapore)

Author keywords

Antibacterial peptide; Antimicrobial peptide; Candida; MRSA; Pseudomonas; Skin infection

Indexed keywords

ANTIINFECTIVE AGENT; GENTAMICIN; NANOPEPTIDE; NYSTATIN; OCTAPEPTIDE; OMIGANAN; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 84922074141     PISSN: 15733149     EISSN: 15733904     Source Type: Journal    
DOI: 10.1007/s10989-014-9440-x     Document Type: Article

References (49)

1. Abbassi F, Lequin O, Piesse C, Goasdoué N, Foulon T, Nicolas T et al (2010) Temporin-SHf, a new type of phe-rich and hydrophobic ultrashort antimicrobial peptide. J Biol Chem 285:16880-16892
2. Andersson DI, Hughes D (2014) Microbiological effects of sublethal levels of antibiotics. Nat Rev Microbiol 12:465-478
3. Athar MA, Winner HI (1971) Development of resistance by Candida species to polyene antibiotics in vitro. J Med Microbiol 4:505-517
4. Bassetti M, Merelli M, Temperoni C, Astilean A (2013) New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob 12:22
5. Bisht GS, Rawat DS, Kumar A, Kumar R, Pasha S (2007) Antimicrobial activity of rationally designed amino terminal modified peptides. Bioorg Med Chem Lett 17:4343-4346
6. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12
7. Brogden NK, Brogden KA (2011) Will new generations of modified antimicrobial peptides improve their potential as pharmaceuticals? Int J Antimicrob Agents 38:217-225
8. Catiau L, Traisnel J, Delval-Dubois V, Chihib N, Guillochon D, Nedjar-Arroume N (2011a) Minimal antimicrobial peptidic sequence from hemoglobin alpha-chain: KYR. Peptides 32:633-638
9. Catiau L, Traisnel J, Chihib N, Le Flem G, Blanpain A, Melnyk O et al (2011b) RYH: A minimal peptidic sequence obtained from beta-chain hemoglobin exhibiting an antimicrobial activity. Peptides 32:1463-1468
10. Clinical and Laboratory Standards Institute (2006) Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. Document M100-S16. CLSI, Wayne
11. Cutuli M, Cristiani S, Lipton JM, Catania A (2000) Antimicrobial effects of α-MSH peptides. J Leukoc Biol 67:233-239
12. Dryden MS (2010) Complicated skin and soft tissue infection. J Antimicrob Chemother 65(Suppl 3): iii35-44
13. Fimland G, Eijsink VG, Nissen-Meyer J (2002) Mutational analysis of the role of tryptophan residues in an antimicrobial peptide. Biochemistry 41:9508-9515
14. Fjell CD, Hiss JA, Hancock REW, Schneider G (2012) Designing antimicrobial peptides: form follows function. Nat Rev Drug Discov 11:37-51
15. Gopal R, Kim YJ, Seo CH, Hahm KS, Park Y (2011) Reversed sequence enhances antimicrobial activity of a synthetic peptide. J Pept Sci 17:329-334
16. Guzmán F, Marshall S, Ojeda C, Albericio F, Carvajal-Rondanelli P (2013) Inhibitory effect of short cationic homopeptides against Gram-positive bacteria. J Pept Sci 19:792-800
17. Hancock REW (2000) Cationic antimicrobial peptides: towards clinical applications. Exp Opin Invest Drugs 9:1723-1729
18. Hancock REW, Sahl H (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551-1557
19. Hilpert K, Volkmer-Engert R, Walter T, Hancock REW (2005) High-throughput generation of small antibacterial peptides with improved activity. Nat Biotechnol 23:1008-1012
20. Hilpert K, Elliott M, Jenssen H, Kindrachuk J, Fjell CD, Körner J et al (2009) Screening and characterization of surface-tethered cationic peptides for antimicrobial activity. Chem Biol 16:58-69
21. Hitchcock CA, Barrett-Bee KJ, Russell NJ (1987) The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. J Med Vet Mycol 25:29-37
22. King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM (2006) Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann Intern Med 144:309-317
23. Liakopoulou-Kyriakides M, Pachatouridis C, Ekateriniadou L, Papageorgiou VP (1997) A new synthesis of the tripeptide Gly-His-Lys with antimicrobial activity. Amino Acids 13:155-161
24. Limbago B, Fosheim GE, Schoonover V, Crane CE, Nadle J, Petit S et al (2009) Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. J Clin Microbiol 47:1344-1351
25. Liu Z, Brady A, Young A, Rasimick B, Chen K, Zhou C et al (2007) Length effects in antimicrobial peptides of the (RW)n series. Antimicrob Agents Chemother 51:597-603
26. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB et al (2006) Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 355:666-674
27. Murugan RN, Jacob B, Kim EH, Ahn M, Sohn H, Seo JH et al (2013) Non hemolytic short peptidomimetics as a new class of potent and broad-spectrum antimicrobial agents. Bioorg Med Chem Lett 23:4633-4636
28. Nagarajan K, Senthamarai R, Devi K, Deepa SS, Anandh N, Krishnaveni P et al (2008) Assessment of antimicrobial activity for the smaller chain dipeptides and tripeptides. J Cell Tissue Res 8:1265-1269
29. Naidoo VB, Rautenbach M (2013) Self-assembling organo-peptide bolaphiles with KLK tripeptide head groups display selective antibacterial activity. J Pept Sci 19:784-791
30. Ong ZY, Gao SJ, Yang YY (2013) Short synthetic β-sheet forming peptide amphiphiles as broad spectrum antimicrobials with antibiofilm and endotoxin neutralizing capabilities. Adv Funct Mater 23:3682-3692
31. Pérez-Vázquez M, Vindel A, Marcos C, Oteo J, Cuevas O, Trincado P et al (2009) Spread of invasive Spanish Staphylococcus aureus spa-type t067 associated with a high prevalence of the aminoglycoside-modifying enzyme gene ant(4′)-Ia and the efflux pump genes msrA/msrB. J Antimicrob Chemother 63:21-31
32. Qi X, Zhou C, Li P, Xu W, Cao Y, Ling H et al (2010) Novel short antibacterial and antifungal peptides with low cytotoxicity: efficacy and action mechanisms. Biochem Biophys Res Commun 398:594-600
33. Ramón-García S, Mikut R, Ng C, Ruden S, Volkmer R, Reischl M et al (2013) Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother 57:2295-2303
34. Rathinakumar R, Walkenhorst WF, Wimley WC (2009) Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity. J Am Chem Soc 131:7609-7617
35. Romanelli A, Moggio L, Montella RC, Campiglia P, Iannaccone M, Capuano F et al (2011) Peptides from royal jelly: studies on the antimicrobial activity of jelleins, jelleins analogs and synergy with temporins. J Pept Sci 17:348-352
36. Sader HS, Fedler KA, Rennie RP, Stevens S, Jones RN (2004) Omiganan pentahydrochloride (MBI 226), a topical 12-aminoacid cationic peptide: spectrum of antimicrobial activity and measurements of bactericidal activity. Antimicrob Agents Chemother 48:3112-3118
37. Schmitz FJ, Fluit AC, Gondolf M, Beyrau R, Lindenlauf E, Verhoef J et al (1999) The prevalence of aminoglycoside resistance and corresponding resistance genes in clinical isolates of staphylococci from 19 European hospitals. J Antimicrob Chemother 43:253-259
38. Segal E (2005) Candida, still number one - what do we know and where are we going from there? Mycoses 48(Suppl. 1):3-11
39. Selby NM, Shaw S, Woodier N, Fluck RJ, Kolhe NV (2009) Gentamicin-associated acute kidney injury. QJM 102:873-880
40. Shin S, Kim JK, Lee JY, Jung KW, Hwang JS, Lee J et al (2009) Design of potent 9-mer antimicrobial peptide analogs of protaetiamycine and investigation of mechanism of antimicrobial action. J Pept Sci 15:559-568
41. Shooshtarizadeh P, Zhang D, Chich J, Gasnier C, Schneider F, Haïkel Y et al (2010) The antimicrobial peptides derived from chromogranin/secretogranin family, new actors of innate immunity. Regul Pept 165:102-110
42. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM et al (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164
43. Strøm MB, Rekdal Ø, Svendsen JS (2002) Antimicrobial activity of short arginine- and tryptophan-rich peptides. J Pept Sci 8:431-437
44. Strøm MB, Haug BF, Skar ML, Stensen W, Stiberg T, Svendsen JS (2003) The pharmacophore of short cationic antibacterial peptides. J Med Chem 46:1567-1570
45. Wei SY, Wu JM, Kuo YY, Chen HL, Yip BS, Tzeng SR et al (2006) Solution structure of a novel tryptophan-rich peptide with bidirectional antimicrobial activity. J Bacteriol 188:328-334
46. Wimley WC (2010) Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 5:905-917
47. Yeung ATY, Gellatly SL, Hancock REW (2011) Multifunctional cationic host defence peptides and their clinical applications. Cell Mol Life Sci 68:2161-2176
48. Zanetti M (2004) Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 75:39-48
49. Zorko M, Japelj B, Hafner-Bratkovič I, Jerala R (2009) Expression, purification and structural studies of a short antimicrobial peptide. Biochim Biophys Acta 1788:314-323